Evidence map›Paper›PMID 40382710›Full record

ArticleCirculation. Heart failure2025

Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant.

Vishal N Rao, Brian L Claggett, Michel G Khouri, Amil M Shah, Scott D Solomon, Senthil Selvaraj

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vishal N RaoDivision of Cardiology, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston (V.N.R.).ORCID 0000-0003-3545-4267
Brian L ClaggettDivision of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (B.L.C., S.D.S.).ORCID 0000-0002-4215-9218
Michel G KhouriDivision of Cardiology, Department of Medicine (M.G.K., S.S.), Duke University Medical Center, Durham, NC.ORCID 0009-0002-6235-5176
Amil M ShahDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas (A.M.S.).ORCID 0000-0003-1056-4451
Scott D SolomonDivision of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (B.L.C., S.D.S.).ORCID 0000-0003-3698-9597
Senthil SelvarajDivision of Cardiology, Department of Medicine (M.G.K., S.S.), Duke University Medical Center, Durham, NC.ORCID 0000-0001-8418-7623

Funding

Building on GWAS for NHLBI-disease: the CHARGE consortiumRC2HL102419 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BOERWINKLE, ERIC A. · 2009 to 2010
$27.6M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2022 to 2025
$4.7M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Quantifying cardiac structure and function to define the progression to hear failure in African AmericansR01HL143224 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2018 to 2021
$3.4M
Proteomic signatures to identifypathways underlying the progression toheart failureR01HL148218 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M, YU, BING · 2020 to 2023
$3.4M
Dissecting the Ketone Metabolic Axis in Heart Failure with Reduced Ejection FractionK23HL161348 · NHLBI · DUKE UNIVERSITY · PI Senthil Selvaraj · 2022 to 2026
$1.0M
Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS K23 HL161348NHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL135008NHLBI NIH HHS R01 HL143224NHLBI NIH HHS R01 HL148218NHLBI NIH HHS R01 HL150342NHLBI NIH HHS RC2 HL102419
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

amyloidosisechocardiographyheart failurelinear modelsprealbumin

Identifiers

PMID40382710
PMCPMC12313242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.